Pre-Op Weight Loss Improves Outcomes of Bariatric Surgery
TUESDAY, Feb. 13, 2018 -- Excess weight loss (EWL) immediately preceding bariatric surgery is associated with improved outcomes, according to a study published online Feb. 2 in the Journal of the American College of Surgeons.
Deborah A. Hutcheon, D.C.N., from the Greenville Health System in South Carolina, and colleagues examined the impact of short-term preoperative EWL on postoperative outcomes for 167 patients who underwent sleeve gastrectomy and 188 who underwent Roux-en-Y gastric bypass between 2014 and 2016. The patients were divided into two cohorts and analyzed according to those who achieved ≥8 percent EWL (224 patients) during a four-week low-calorie diet period immediately preceding surgery and those who did not (131 patients). Primary end points included percent EWL postoperatively at months one, three, six, and 12.
The researchers found that the percentage EWL postoperatively was significantly greater for patients achieving ≥8 percent EWL preoperatively. Specifically, 42.3 versus 36.1 percent (P < 0.001) at postoperative month three, 56.0 versus 47.5 percent (P < 0.001) at postoperative month six, and 65.1 versus 55.7 percent (P = 0.003) at postoperative month 12. Patients achieving ≥8 percent EWL also had lower median operative duration (117 versus 125 minutes; P = 0.061) and lower mean hospital length of stay (1.8 days versus 2.1 days; P = 0.006).
"Preoperative weight loss of ≥8 percent excess weight, while following a four-week low-calorie diet, is associated with a significantly greater rate of postoperative EWL over one year, as well as shorter operative duration and hospital length of stay," the authors write.
© 2020 HealthDay. All rights reserved.
Posted: February 2018
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.